Fat tissue is at the nexus of mechanisms impacting maximum lifespan, timing of age-related disease onset, and metabolic consequences of manipulating the somatotrophic axis. Clinical morbidity, altered secretory profiles, insulin resistance, fat redistribution among depots, and ectopic fat deposition with aging are strikingly delayed by reducing somatotrophic drive. New fat cells develop from their progenitors, preadipocytes, throughout life. Preadipocyte differentiation is impaired and inflammatory cytokine generation, stress responses, and preadipocyte senescence increase with aging. IGF-1 promotes preadipocyte utilization by enhancing replication and differentiation. We propose that lifelong preadipocyte utilization and metabolic stress contribute to age-related fat tissue dysfunction, particularly in subcutaneous fat. Visceral preadipocytes are resistant to IGF-1, potentially contributing to delayed age-related accumulation of visceral fat in animal models with low IGF-1. Our hypothesis is that decreasing somatotrophic drive will reduce subcutaneous preadipocyte utilization with aging, delaying loss and dysfunction, while preventing visceral preadipocyte development into fat, delaying redistribution. We predict interventions that decrease IGF-1 exposure will delay declines in adipogenesis, increases in stress responses, preadipocyte inflammatory cytokine generation, and senescent cell accumulation. Using the unique animal models in this Project, we will dissect contributions of IGF-1 vs. GH and local fat tissue vs. systemic IGF-1.
In Aim 1, we will test if decreasing IGF-1 will: 1) reduce subcutaneous preadipocyte utilization with aging, preserving adipogenic capacity and delaying stress-responsive anti-adipogenic factor expression, and 2) impair visceral preadipocyte development into fat.
Aim 2 is to test if reducing IGF-1 exposure will delay age-related development of a metabolically unfavorable preadipocyte secretory profile with increased inflammatory cytokine, chemokine, and matrix remodeling protein production.
Aim 3 is to test if generation of senescent preadipocytes, which we found accumulate with aging, particularly in subcutaneous fat, and which may reflect progenitor overutilization and metabolic stress, is delayed by reducing life-long IGF-1 exposure. These studies will address critical knowledge gaps in aging and fat tissue function, pave the way for further analysis, and suggest potential mechanism-based interventions.

Public Health Relevance

Fat tissue is at the nexus of mechanisms impacting maximum lifespan and timing of age-related disease onset. Age-related disease, insulin resistance, and fat redistribution are delayed by reducing growth hormone or insulin-like growth factor-1. Our hypothesis is that decreasing these hormones delays loss and dysfunction of skin fat with aging due to reduced fat cell progenitor dysfunction, while preventing development of progenitors into fat within the abdomen, delaying redistribution. These studies will address critical knowledge gaps in aging and fat tissue function and suggest potential mechanism-based treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG031736-05
Application #
8448206
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
2015-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2013
Total Cost
$345,456
Indirect Cost
$29,610
Name
Southern Illinois University School of Medicine
Department
Type
DUNS #
038415006
City
Springfield
State
IL
Country
United States
Zip Code
62794
Xu, Ming; Tchkonia, Tamar; Kirkland, James L (2016) Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction. Pharmacol Res 111:152-4
Bartke, A; Sun, L; Fang, Y et al. (2016) Growth hormone actions during development influence adult phenotype and longevity. Exp Gerontol 86:22-27
Saccon, Tatiana D; Moreira, Fabiana; Cruz, Luis A et al. (2016) Ovarian aging and the activation of the primordial follicle reserve in the long-lived Ames dwarf and the short-lived bGH transgenic mice. Mol Cell Endocrinol :
Hascup, Kevin N; Lynn, Mary K; Fitzgerald, Patrick J et al. (2016) Enhanced Cognition and Hypoglutamatergic Signaling in a Growth Hormone Receptor Knockout Mouse Model of Successful Aging. J Gerontol A Biol Sci Med Sci :
Palmer, Allyson K; Kirkland, James L (2016) Aging and adipose tissue: potential interventions for diabetes and regenerative medicine. Exp Gerontol 86:97-105
Liu, Yang; Knop, Erich; Knop, Nadja et al. (2016) Growth Hormone Influence on the Morphology and Size of the Mouse Meibomian Gland. J Ophthalmol 2016:5728071
Bartke, Andrzej; List, Edward O; Kopchick, John J (2016) The somatotropic axis and aging: Benefits of endocrine defects. Growth Horm IGF Res 27:41-5
Bartke, Andrzej (2016) Healthspan and longevity can be extended by suppression of growth hormone signaling. Mamm Genome 27:289-99
Dominick, Graham; Bowman, Jacqueline; Li, Xinna et al. (2016) mTOR regulates the expression of DNA damage response enzymes in long-lived Snell dwarf, GHRKO, and PAPPA-KO mice. Aging Cell :
Hascup, Erin R; Wang, Feiya; Kopchick, John J et al. (2016) Inflammatory and Glutamatergic Homeostasis Are Involved in Successful Aging. J Gerontol A Biol Sci Med Sci 71:281-9

Showing the most recent 10 out of 131 publications